While other molecules are still under evaluation for PCa theranostics [41, 42], PSMA RLT is already indicated for mCRPC patients exhibiting one or more metastatic lesions that show high PSMA PET expression (above half of the parotid uptake). Here, FOLH1 is linked to posterior cortical atrophy.